BEIJING -- Anti-poverty work will continue its momentum in Tibet to ensure the autonomous region does not fall behind in the national endeavor of building a "moderately prosperous society" by 2020, a regional official said. By the end of 2016, Tibet had 442,000 people living below the poverty line, and the poverty rate was higher than the national average. The total population in the region is about 3.2 million. "Poverty remains a deep-seated problem in at least 33 counties in Tibet," said Norbu Dondrup, vice chairman of the regional government, while answering questions from reporters Thursday on the sidelines of the 19th National Congress of the Communist Party of China. The government will make differentiated poverty-relief policies that suit every county and every household. Funds and poverty-relief programs will be applied to the poorest counties. More people will move from harsh environments to cities and areas with better infrastructure, he said. The government will help herders and farmers develop industries. Children of poor families will receive free college education, and the government will help young graduates from poor families find jobs and start businesses so they can better support their family, Norbu Dondrup said. The region will coordinate economic development with environmental protection. It will create more jobs at national parks and develop tourism. Living conditions for border residents will be improved, he said. Officials tasked with poverty relief work will be subject to real-time appraisal from their superiors, and those who slack or fail will be punished, he added. printable wristbandssilicone wristbands24 wristbandscustom livestrong braceletscustom made rubber braceletscustom fidget spinners
HONG KONG - A research team led by scientists of the University of Hong Kong (HKU) announced Thursday the invention of a universal antibody drug against HIV/AIDS that can "kill two birds with one stone."By engineering a tandem bi-specific broadly neutralizing antibody (bNAb), the team found that this novel antibody drug is universally effective not only against all genetically divergent global HIV-1 strains tested, but also promoting the elimination of latently infected cells in a humanized mouse model, the team announced at a press conference.The single gene-encoded tandem bNAb titled "BiIA-SG" strategically ambushes invading HIV-1 particles to protect CD4 positive T cells by attaching to host protein CD4. BiIA-SG not only displays a potent activity against all three panels of 124 genetically divergent global HIV-1 strains tested, but also prevents diverse live viral challenges completely in humanized mice.Moreover, gene transfer of BiIA-SG achieves pro-longed drug availability in vivo, leading to a promising efficacy of eliminating HIV-1 infected cells in humanized mice.With significantly improved breadth and potency, BiIA-SG will hopefully be the first "made in Hong Kong" anti-HIV-1 antibody drug for clinical development, the team said.The research team was led by scientists at AIDS Institute and Department of Microbiology of HKU's Li Ka Shing Faculty of Medicine. The new findings were published in the April issue of Journal of Clinical Investigation, one of the world's leading biomedical journals.
